MOUNTAIN VIEW, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (Nasdaq:BAVA) announced today that the Company will be hosting Congresswoman Anna Eshoo (D-CA) and David Gollaher, President & CEO of the California Healthcare Institute at the corporate headquarters for its Bavarian Nordic ImmunoTherapeutics subsidiary in Mountain View, CA on February 21, 2013. During the visit, Representative Eshoo and Mr. Gollaher will meet with management to discuss the impact of recently passed legislation as well as the benefits of innovative public-private partnerships in cancer and biodefense.
Representative Eshoo is a lead sponsor of the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 as well as the Recalcitrant Cancer Research Act. The Recalcitrant Cancer Research Act was signed into law by President Obama as a part of the National Defense Authorization Act on January 3, 2013. The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 is expected to be signed into law in the coming weeks.
"We're honored that Representative Eshoo will visit Bavarian Nordic to learn more about the opportunities and challenges facing an entrepreneurial immunotherapy company," said Anders Hedegaard, President and CEO of Bavarian Nordic A/S. "We applaud her efforts to introduce legislation that encourages the development of early detection methods and better treatment options to improve cancer outcomes as well as medical countermeasures and are confident that such efforts will promote the continued growth of the life science industry and get innovations to patients faster."
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC(R), a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC(R) has been tested in nearly 600 patients. In infectious diseases, the company's lead program is IMVAMUNE(R), a non-replicating smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. For more information, visit www.bavarian-nordic.com
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
James Breitmeyer, Division President Cancer Vaccines. Phone +1-650-213-4968
Source:Bavarian Nordic A/S